Drug Trial Radar · NCT06285370
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
May 29, 2023
Primary completion
Aug 12, 2025
Study completion Nov 10, 2025
Sponsor
- Lead sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy
Conditions
- Cutaneous T-Cell Lymphoma
Interventions
MogamulizumabDrug
Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital, Department of Dermatology and Venereology
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center, Department of Medical Oncology
Guangzhou, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
ZheJiang Cancer Hospital
Hangzhou, Zhejiang, China
First Affiliated Hospital of Zhengzhou University
Henan, Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.